Page 1 of 1

The Currently Incurable Scientist: The Future of anti-EGFR Therapy?

Posted: Thu Aug 13, 2015 5:06 pm
by DK37
Hi Everyone,

My next "The Currently Incurable Scientist" monthly column on the Fight Colorectal Cancer website published today.

It is a two-part column called "The Future of anti-EGFR Therapy?"

Part 1 examines the current anti-EGFR therapies approved for KRAS-wild type CRC & areas for potential improvement.
http://fightcolorectalcancer.org/resear ... py-part-1/

Part 2 discusses a few next-generation anti-EGFR strategies currently in clinical trials: "Sym004" and "Imprime PGG".
http://fightcolorectalcancer.org/resear ... py-part-2/

I hope you find these posts informative & useful! The columns are word-count limited, so please feel free to ask follow-up questions in the comments below!

-DK

Re: The Currently Incurable Scientist: The Future of anti-EGFR Therapy?

Posted: Fri Aug 14, 2015 12:23 am
by ieowi
Thank you DK, I always switch Siri to auto read pages and just finished listening to your articles while driving ;).
Thank you for posting them I always learn a lot from your posts.

If you don't mind I have two questions ;

1- from the two future drugs which one is more promising in your opinion ?
2- for patients with no kras wiled mutation is there anything out there that may help them ?
Or future drug ?

Re: The Currently Incurable Scientist: The Future of anti-EGFR Therapy?

Posted: Fri Aug 14, 2015 1:30 am
by Nik Colon
Thanks again DK

Re: The Currently Incurable Scientist: The Future of anti-EGFR Therapy?

Posted: Fri Aug 14, 2015 10:07 am
by DK37
ieowi wrote:
If you don't mind I have two questions ;

1- from the two future drugs which one is more promising in your opinion ?
2- for patients with no kras wiled mutation is there anything out there that may help them ?
Or future drug ?


Hi ieowi,

1 - That is a really tough question to answer. I have anecdotally heard of complete response patients on both. They are currently going after different patient populations however, so that may be a better way to guide choice than to try to figure out "which is better in general" based upon very limited information. Sym004 is curently being targetted towards as a "second line" therapy patients who had responded to Erbitux or Vectibix and have become resistant - so if you are in that group, sym004 is currently the one to consider. If you are KRAS-wt and considering going on Erbitux as standard care as your first EGFR-inhibitor, that is a time to consider entering the Imprime PGG trial.

2- to correct terminology "KRAS-wild type" is not a mutation, the term "wild-type" = "non-mutated". But I think you are probably asking about options for KRAS-mutated folks. I posted before some preliminary results (first ~20 patients) on "RRx-001" that showed a pretty high response rate even if KRAS-mutated (just search posts for RRx-001). So that is one to consider which has released clinical data. There are others as well which have released less detailed information that appear KRAS-agnostic. In terms of future drugs, many/most immunotherapies will probably not care about KRAS-status. On the flip side - our own Celine appears to be potentially having activity in the NIH TIL trial ---- not only is she KRAS-mut but the TIL they are using for her is actually targetting her KRAS mutant protein!

Hope that helps,
-DK

Re: The Currently Incurable Scientist: The Future of anti-EGFR Therapy?

Posted: Sat Aug 15, 2015 2:28 am
by ieowi
thank you DK37, i am going through what you mentioned :D